Funding

The biotech Pretzel Research has been awarded a total of $72.5 million in Series A funding. Pretzel develops therapeutics that target the mitochondria, often referred to as “the powerhouse of the cell.” There are many diseases caused by mitochondrial dysfunction and even more that are affected by it. To start, Prezel will focus on “primary” mitochondrial disorder, which affect 1 out of every 5,000 people.